Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ONY
Surfactant therapy can be life-saving for newborn infants with respiratory distress due to surfactant insufficiency, also known as respiratory distress syndrome (RDS). All commercially available surfactants for clinical use are approved for administration through an endotracheal tube. Placement of an endotracheal tube, a procedure called intubation, is stressful for the infant and associated with significant adverse effects. The proposed supraglottic instillation device allows infants to benefit from surfactant therapy while avoiding the negative effects of intubation.
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Gestational age at the time of enrollment ≥ 24 0/7 weeks
Weight at the time of enrollment 500- 5000 grams
Age ≤ 24 hours old
Require non-invasive respiratory support (i.e. continuous positive airway pressure, high flow nasal cannula or non-invasive ventilation)
Require FiO2 ≤ 40%
Clinical diagnosis of RDS
You may not be if
Prior surfactant administration
Prior mechanical ventilation
Major congenital anomaly
Abnormality of the airway
Respiratory distress secondary to an etiology other than RDS (suspected pulmonary hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or hypovolemia shock, hypoxic ischemic encephalopathy)